[Mycophenolate mofetil in lupus nephritis refractory to intravenous cyclophosphamide].

Objective: To evaluate the use of mycophenolate mofetil (MMF) in lupus nephritis (LN) patients with prior failure to intravenous cyclophosphamide over a 12-month follow-up.

Patients And Methods: Eleven patients with LN were included. MMF doses ranged from 1.